The University of Southampton
University of Southampton Institutional Repository

Percutaneous left ventricular unloading during high-risk coronary intervention: rationale and design of the CHIP-BCIS3 randomized controlled trial

Percutaneous left ventricular unloading during high-risk coronary intervention: rationale and design of the CHIP-BCIS3 randomized controlled trial
Percutaneous left ventricular unloading during high-risk coronary intervention: rationale and design of the CHIP-BCIS3 randomized controlled trial

INTRODUCTION: Percutaneous coronary intervention for complex coronary disease is associated with a high risk of cardiogenic shock. This can cause harm and limit the quality of revascularization achieved, especially when left ventricular function is impaired at the outset. Elective percutaneous left ventricular unloading is increasingly used to mitigate adverse events in patients undergoing high-risk percutaneous coronary intervention, but this strategy has fiscal and clinical costs and is not supported by robust evidence. METHODS: CHIP-BCIS3 (Controlled Trial of High-Risk Coronary Intervention With Percutaneous Left Ventricular Unloading) is a prospective, multicenter, open-label randomized controlled trial that aims to determine whether a strategy of elective percutaneous left ventricular unloading is superior to standard care (no planned mechanical circulatory support) in patients undergoing nonemergent high-risk percutaneous coronary intervention. Patients are eligible for recruitment if they have severe left ventricular systolic dysfunction, extensive coronary artery disease, and are due to undergo complex percutaneous coronary intervention (to the left main stem with calcium modification or to a chronic total occlusion with a retrograde approach). Cardiogenic shock and acute ST-segment–elevation myocardial infarction are exclusions. The primary outcome is a hierarchical composite of all-cause death, stroke, spontaneous myocardial infarction, cardiovascular hospitalization, and periprocedural myocardial infarction, analyzed using the win ratio. Secondary outcomes include completeness of revascularization, major bleeding, vascular complications, health economic analyses, and health-related quality of life. A sample size of 250 patients will have in excess of 80% power to detect a hazard ratio of 0.62 at a minimum of 12 months, assuming 150 patients experience an event across all follow-up. CONCLUSIONS: To date, 169 patients have been recruited from 21 National Health Service hospitals in the United Kingdom, with recruitment expected to complete in 2024. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05003817. GRAPHIC ABSTRACT: A graphic abstract is available for this article.

coronary artery disease, heart-assist devices, left ventricular systolic dysfunction, percutaneous coronary intervention, randomized controlled trial
1941-7640
E013367
Ryan, Matthew
40fee3d1-1262-44aa-b973-fff0b930af12
Ezad, Saad M.
01c5ca05-0075-464e-9dd7-a90173cbe8ea
Webb, Ian
fb6c15e0-17b6-44ac-8941-ea5a1c954f44
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
the CHIP-BCIS3 Investigators
Ryan, Matthew
40fee3d1-1262-44aa-b973-fff0b930af12
Ezad, Saad M.
01c5ca05-0075-464e-9dd7-a90173cbe8ea
Webb, Ian
fb6c15e0-17b6-44ac-8941-ea5a1c954f44
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4

Ryan, Matthew, Ezad, Saad M. and Webb, Ian , the CHIP-BCIS3 Investigators (2024) Percutaneous left ventricular unloading during high-risk coronary intervention: rationale and design of the CHIP-BCIS3 randomized controlled trial. Circulation Cardiovascular Interventions, 17 (3), E013367, [e013367]. (doi:10.1161/CIRCINTERVENTIONS.123.013367).

Record type: Article

Abstract

INTRODUCTION: Percutaneous coronary intervention for complex coronary disease is associated with a high risk of cardiogenic shock. This can cause harm and limit the quality of revascularization achieved, especially when left ventricular function is impaired at the outset. Elective percutaneous left ventricular unloading is increasingly used to mitigate adverse events in patients undergoing high-risk percutaneous coronary intervention, but this strategy has fiscal and clinical costs and is not supported by robust evidence. METHODS: CHIP-BCIS3 (Controlled Trial of High-Risk Coronary Intervention With Percutaneous Left Ventricular Unloading) is a prospective, multicenter, open-label randomized controlled trial that aims to determine whether a strategy of elective percutaneous left ventricular unloading is superior to standard care (no planned mechanical circulatory support) in patients undergoing nonemergent high-risk percutaneous coronary intervention. Patients are eligible for recruitment if they have severe left ventricular systolic dysfunction, extensive coronary artery disease, and are due to undergo complex percutaneous coronary intervention (to the left main stem with calcium modification or to a chronic total occlusion with a retrograde approach). Cardiogenic shock and acute ST-segment–elevation myocardial infarction are exclusions. The primary outcome is a hierarchical composite of all-cause death, stroke, spontaneous myocardial infarction, cardiovascular hospitalization, and periprocedural myocardial infarction, analyzed using the win ratio. Secondary outcomes include completeness of revascularization, major bleeding, vascular complications, health economic analyses, and health-related quality of life. A sample size of 250 patients will have in excess of 80% power to detect a hazard ratio of 0.62 at a minimum of 12 months, assuming 150 patients experience an event across all follow-up. CONCLUSIONS: To date, 169 patients have been recruited from 21 National Health Service hospitals in the United Kingdom, with recruitment expected to complete in 2024. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05003817. GRAPHIC ABSTRACT: A graphic abstract is available for this article.

Text
ryan-et-al-2024-percutaneous-left-ventricular-unloading-during-high-risk-coronary-intervention-rationale-and-design-of - Version of Record
Available under License Creative Commons Attribution.
Download (852kB)

More information

Accepted/In Press date: 4 January 2024
e-pub ahead of print date: 27 February 2024
Published date: 1 March 2024
Additional Information: Publisher Copyright: © 2024 Lippincott Williams and Wilkins. All rights reserved.
Keywords: coronary artery disease, heart-assist devices, left ventricular systolic dysfunction, percutaneous coronary intervention, randomized controlled trial

Identifiers

Local EPrints ID: 492121
URI: http://eprints.soton.ac.uk/id/eprint/492121
ISSN: 1941-7640
PURE UUID: 5979b1f9-d07a-4728-b032-7826ba48b323
ORCID for Nick Curzen: ORCID iD orcid.org/0000-0001-9651-7829

Catalogue record

Date deposited: 17 Jul 2024 16:32
Last modified: 24 Jul 2024 01:39

Export record

Altmetrics

Contributors

Author: Matthew Ryan
Author: Saad M. Ezad
Author: Ian Webb
Author: Nick Curzen ORCID iD
Corporate Author: the CHIP-BCIS3 Investigators

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×